These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573 [TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C; Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010 [TBL] [Abstract][Full Text] [Related]
11. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR. Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542 [TBL] [Abstract][Full Text] [Related]
12. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219 [TBL] [Abstract][Full Text] [Related]
13. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551 [TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease monitoring in multiple myeloma. Davies FE; Rawstron AC; Owen RG; Morgan GJ Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924 [TBL] [Abstract][Full Text] [Related]
16. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides. Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584 [TBL] [Abstract][Full Text] [Related]
17. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130 [TBL] [Abstract][Full Text] [Related]
18. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451 [TBL] [Abstract][Full Text] [Related]
19. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253 [TBL] [Abstract][Full Text] [Related]
20. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]